HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NPA Agrees To Drop Complaint Of 'Shadow Board' Plot To Oust Fabricant

This article was originally published in The Rose Sheet

Executive Summary

NPA reaches a settlement to its complaint alleging current and former board members plotted to oust CEO Daniel Fabricant. The trade group remains embroiled in a wrongful dismissal complaint filed by former CFO Brent Weickert.

You may also be interested in...



NPA Broadens Retail Membership: Health And Wellness Industry News Roundup

NPA cuts board to nine members; GMP warning for Kumato Labs; Juice Garden product names are claims in UK; Consumer Safety Coalition questions Reckitt’s MJN acquisition; and CRN, ACI develop regulatory conference agenda.

NPA Board Members Argue Investigating The CEO Was Part Of Their Job

NPA's amended complaint includes a purported email trail showing the self-professed "shadow board" plotted to remove CEO Daniel Fabricant. In a motion to dismiss, board members argue that while NPA alleges "a breach of fiduciary duty … they satisfied, rather than violated, their fiduciary duties."

NPA Claims Board Members, Former CFO 'Colluded' To Discredit, Dismiss Fabricant

The complaint filed in federal court in Washington alleges a "long-planned surprise attack" as part of an attempt by representatives of the retail sector on the NPA board and by former chief financial officer Brent Weickert to discredit the trade group's executive director and CEO, Daniel Fabricant.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS109020

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel